Recombinant apolipoproteins for the treatment of vascular diseases

Atherosclerosis

Volumn 142, Issue 1, 1999, Pages 29-40

  Sirtori, Cesare R ^a   Calabresi, Laura ^a   Franceschini, Guido ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Apoliproteins; Insulin; Lipoproteins

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN E; FIBROBLAST GROWTH FACTOR; RECOMBINANT APOLIPOPROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; CHOLESTEROL METABOLISM; DRUG MECHANISM; IMMUNOGENICITY; INTRAVENOUS DRUG ADMINISTRATION; LIPOPROTEIN METABOLISM; NONHUMAN; PRIORITY JOURNAL; RABBIT; REVIEW; TECHNOLOGY; VASCULAR DISEASE;

ANIMALS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; HUMANS; RECOMBINANT PROTEINS;

EID: 0032890429     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00247-0     Document Type: Review

References (159)

1. Akerlof E.O., Jornvall H., Slotte H., Pousette A. Identification of apolipoprotein A1 and immunoglobulin as components of a serum complex that mediates activation of human sperm motility. Biochemistry. 30:1991;8986-8990.
2. Nathan B.P., Chang K.C., Bellosta S., Brisch E., Ge N., Mahley R.W., Pitas R.E. The inhibitory effect of apolipoprotein E4 on neurite outgrowth is associated with microtubule depolymerization. J. Biol. Chem. 270:1995;19791-19799.
3. Fujimoto K., Fukagawa K., Sakata T., Tso P. Suppression of food intake by apolipoprotein A-IV is mediated through the central nervous system in rats. J. Clin. Invest. 91:1993;1830-1833.
4. Owens B.J., Anantharamaiah G.M., Kahlon J.B., Srinivas R.V., Compans R.W., Segrest J.P. Apolipoprotein A-I and its amphipathic helix peptide analogues inhibit human immunodeficiency virus-induced syncytium formation. J. Clin. Invest. 86:1990;1142-1150.
5. Hubsch A.P., Powell F.S., Lerch P.G., Doran J.E. A reconstituted, apolipoprotein A-I containing lipoprotein reduces tumor necrosis factor release and attenuates shock in endotoxemic rabbits. Circ. Shock. 40:1993;14-23.
6. Mahley R.W., Innerarity T.L., Rall S.C., Weisgraber K.H. Plasma lipoproteins: apolipoprotein structure and function. J. Lipid Res. 25:1984;1277-1294.
7. Segrest J.P., Jones M.K., De Loof H., Brouillette C.G., Venkatachalapathi Y.V., Anantharamaiah G.M. The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function. J. Lipid Res. 33:1992;141-166.
8. Glomset J.A. The plasma lecithin:cholesterol acyltransferase reaction. J. Lipid Res. 9:1968;155-162.
9. Gordon D.J., Rifkind B.M. High density lipoprotein: the clinical implications of recent studies. N. Engl. J. Med. 321:1989;1311-1316.
10. Rothblat G.H., Mahlberg F.H., Johnson W.J., Phillips M.C. Apolipoproteins, membrane cholesterol domains, and the regulation of cholesterol efflux. J. Lipid Res. 33:1992;1091-1097.
11. Jonas A. Lecithin-cholesterol acyltransferase in the metabolism of high-density lipoproteins. Biochim. Biophys. Acta. 1084:1991;205-220.
12. Allan C.M., Fidge N.H., Morrison J.R., Kanellos J. Monoclonal antibodies to human apolipoprotein AI: probing the putative receptor binding domain of apolipoprotein AI. Biochem. J. 290:1993;449-455.
13. Rubin E.M., Krauss R.M., Spangler E.A., Verstuyft J.G., Clift S.M. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 353:1991;265-267.
14. Paszty C., Maeda N., Verstuyft J., Rubin E.M. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J. Clin. Invest. 94:1994;899-903.
15. Duverger N., Kruth H., Emmanuel F., Caillaud J.M., Viglietta C., Castro G.R., Tailleux A., Fievet C., Fruchart J.C., Houdebine L.M., Denefle P., Castro G. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. Circulation. 94:1996;713-717.
16. De Geest B., Zhao Z., Collen D., Holvoet P. Effects of adenovirus-mediated human apo A-I gene transfer on neointima formation after endothelial denudation in apo E-deficient mice. Circulation. 96:1997;4349-4356.
17. Brewer H.B. Jr., Fairwell T., Larue A., Ronan R., Houser A., Bronzert T.J. The amino acid sequence of human apo A-I, an apolipoprotein isolated from high density lipoprotein. Biochem. Biophys. Res. Commun. 80:1978;623-630.
18. Wald J.H., Krul E.S., Jonas A. Structure of apolipoprotein A-I in three homogeneous, reconstituted high density lipoprotein particles. J. Biol. Chem. 32:1990;20037-20043.
19. Brouillette C.G., Anantharamaiah G.M. Structural models of human apolipoprotein A-I. Biochim. Biophys. Acta. 1256:1995;103-129.
20. Ji Y., Jonas A. Properties of an N-terminal proteolytic fragment of apolipoprotein AI in solution and in reconstituted high density lipoproteins. J. Biol. Chem. 270:1995;11290-11297.
21. Schmidt H.H., Remaley A.T., Stonik J.A., Ronan R., Wellmann A., Thomas F., Zech L.A., Brewer H.B. Jr., Hoeg J.M. Carboxyl-terminal domain truncation alters apolipoprotein A-I in vivo catabolism. J. Biol. Chem. 270:1995;5469-5475.
22. Meng Q.H., Calabresi L., Fruchart J.C., Marcel Y.L. Apolipoprotein A-I domains involved in the activation of lecithin:cholesterol acyltransferase. Importance of the central domain. J. Biol. Chem. 268:1993;16966-16973.
23. Mendez A.J., Anantharamaiah G.M., Segrest J.P., Oram J.F. Synthetic amphipathic helical peptides that mimic apolipoprotein A-I in clearing cellular cholesterol. J. Clin. Invest. 94:1994;1698-1705.
24. Vanloo B., Demoor L., Boutillon C., Lins L., Brasseur R., Baert J., Fruchart J.C., Tartar A., Rosseneu M. Association of synthetic peptide fragments of human apolipoprotein A-I with phospholipids. J. Lipid Res. 36:1995;1686-1696.
25. Yancey P.G., Bielicki J.K., Johnson W.J., Lund Katz S., Palgunachari M.N., Anantharamaiah G.M., Segrest J.P., Phillips M.C., Rothblat G.H. Efflux of cellular cholesterol and phospholipid to lipid-free apolipoproteins and class A amphipathic peptides. Biochemistry. 34:1995;7955-7965.
26. Buchko G.W., Treleaven W.D., Dunne S.J., Tracey A.S., Cushley R.J. Structural studies of a peptide activator of human lecithin-cholesterol acyltransferase. J. Biol. Chem. 271:1996;3039-3045.
27. Demoor L., Boutillon C., Fievet C., Vanloo B., Baert J., Rosseneu M., Fruchart J.C., Tartar A. Branched synthetic constructs that mimic the physico-chemical properties of apolipoprotein AI in reconstituted high-density lipoproteins. Eur. J. Biochem. 239:1996;74-84.
28. Labeur C., Lins L., Vanloo B., Baert J., Brasseur R., Rosseneu M. Design of a new class of amphipathic helical peptides for the plasma apolipoproteins that promote cellular cholesterol efflux but do not activate LCAT. Arterioscler. Thromb. Vasc. Biol. 17:1997;580-588.
29. Milano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J. Clin. Invest. 66:1980;892-900.
30. Milano Detection of normal AI in affected subjects and evidence for a cysteine for arginine substitution in the variant AI. J. Biol. Chem. 258:1983;2508-2513.
31. Milano apoprotein with plasma lipid and lipoprotein patterns. Atherosclerosis. 58:1985;159-174.
32. Milano apoprotein. Identification of the complete kindred and evidence of a dominant genetic transmission. Am. J. Hum. Genet. 37:1985;1083-1097.
33. milano.Accelerated binding and dissociation from lipids of a human apolipoprotein variant. J. Biol. Chem. 260:1985;16321-16325.
34. Milano, associated with familial hypoalphalipoproteinemia. J. Clin. Invest. 91:1993;1445-1452.
35. Milano dimer. The introduction of an interchain disulfide bridge remarkably alters the physicochemical properties of apolipoprotein A-I. J. Biol. Chem. 269:1994;32168-32174.
36. Calabresi L., Franceschini G., Burkybile A., Jonas A. Activation of lecithin cholesterol acyltransferase by a disulfide-linked apolipoprotein A-I dimer. Biochem. Biophys. Res. Commun. 232:1997;345-349.
37. Calabresi L., Franceschini G., Sirtori C.R., de Palma A., Saresella M., Ferrante P., Taramelli D. Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins. Biochem. Biophys. Res. Commun. 238:1997;61-65.
38. Calabresi L., Vecchio G., Frigerio F., Vavassori L., Sirtori C.R., Franceschini G. Reconstituted high-density lipoproteins with a disulfide-linked apolipoprotein A-I dimer: evidence for restricted particle size heterogeneity. Biochemistry. 36:1997;12428-12433.
39. Milano. Disulfide-linked dimers increase high density lipoprotein stability and hinder particle interconversion in carrier plasma. J. Biol. Chem. 265:1990;12224-12231.
40. Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. Circulation. 90:1994;1935-1941.
41. Milano dimer inhibits carotid intimal thickening induced by perivascular manipulation in rabbits. Circ. Res. 76:1995;405-411.
42. Shah P.K., Nilsson J., Kaul S., Fishbein M.C., Ageland H., Hamsten A., Johansson J., Karpe F., Cercek B. Effects of recombinant apolipoprotein A-I-Milano on aortic atherosclerosis in apolipoportein E-deficient mice. Circulation. 97:1998;780-785.
43. Westerlund J.A., Weisgraber K.H. Discrete carboxyl-terminal segments of apolipoprotein E mediate lipoprotein association and protein oligomerization. J. Biol. Chem. 268:1993;15745-15750.
44. Wilson C., Wardell M.R., Weisgraber K.H., Mahley R.W., Agard D.A. Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science. 252:1991;1817-1822.
45. Dyer C.A., Curtiss L.K. A synthetic peptide mimic of plasma apolipoprotein E that binds the LDL receptor. J. Biol. Chem. 266:1991;22803-22806.
46. Dyer C.A., Cistola D.P., Parry G.C., Curtiss L.K. Structural features of synthetic peptides of apolipoprotein E that bind the LDL receptor. J. Lipid Res. 36:1995;80-88.
47. Nikoulin I.R., Curtiss L.K. An apolipoprotein E synthetic peptide targets to lipoproteins in plasma and mediates both cellular lipoprotein interactions in vitro and acute clearance of cholesterol-rich lipoproteins in vivo. J. Clin. Invest. 101:1998;223-234.
48. Piedrahita J.A., Zhang S.H., Hagaman J.R., Oliver P.M., Maeda N. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc. Natl. Acad. Sci. USA. 89:1992;4471-4475.
49. Reddick R.L., Zhang S.H., Maeda N. Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression. Arterioscler. Thromb. 14:1994;141-147.
50. Nakashima Y., Plump A.S., Raines E.W., Breslow J.L., Ross R. Apo E-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler. Thromb. 14:1994;133-140.
51. Linton M.F., Atkinson J.B., Fazio S. Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science. 267:1995;1034-1037.
52. Bellosta S., Mahley R.W., Sanan D.A., Murata J., Newland D.L., Taylor J.M., Pitas R.E. Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. J. Clin. Invest. 96:1995;2170-2179.
53. Kashyap V.S., Santamarina-Fojo S., Brown D.R., Parrott C.L., Applebaum-Bowden D., Meyn S., Talley G., Paigen B., Maeda N., Brewer H.B. Apolipoprotein E deficiency in mice: gene replacement and prevention of atherosclerosis using adenovirus vectors. J. Clin. Invest. 96:1995;1612-1620.
54. Mazzone T., Reardon C.A. Expression of heterologous human apolipoprotein E by J774 macrophages enhances cholesterol efflux to HDL3. J. Lipid Res. 35:1994;1345-1353.
55. Saxena U., Ferguson E., Bisgaier C.L. Apolipoprotein E modulates low density lipoprotein retention by lipoprotein lipase anchored to the subendothelial matrix. J. Biol. Chem. 268:1993;14812-14819.
56. Kelly M.E., Clay M.A., Mistry M.J., Hsieh-Li H.M., Harmony J.A. Apolipoprotein E inhibition of proliferation of mitogen-activated T lymphocytes: production of interleukin 2 with reduced biological activity. Cell. Immunol. 159:1994;124-139.
57. Mistry M.J., Clay M.A., Kelly M.E., Steiner M.A., Harmony J.A. Apolipoprotein E restricts interleukin-dependent T lymphocyte proliferation at the G1A/G1B boundary. Cell. Immunol. 160:1995;14-23.
58. Vogel T., Guo N.H., Guy R., Drezlich N., Krutzsch H.C., Blake D.A., Panet A., Roberts D.D. Apolipoprotein E: a potent inhibitor of endothelial and tumor cell proliferation. J. Cell. Biochem. 54:1994;299-308.
59. Riddell D.R., Graham A., Owen J.S. Apolipoprotein E inhibits platelet aggregation through the L-arginine:nitric oxide pathway. Implications for vascular disease. J. Biol. Chem. 272:1997;89-95.
60. Dyer C.A., Smith R.S., Curtiss L.K. Only multimers of a synthetic peptide of human apolipoprotein E are biologically active. J. Biol. Chem. 266:1991;15009-15015.
61. Clay M.A., Anantharamaiah G.M., Mistry M.J., Balasubramaniam A., Harmony J.A. Localization of a domain in apolipoprotein E with both cytostatic and cytotoxic activity. Biochemistry. 34:1995;11142-11151.
62. Brewer H.B. Jr., Ronan R., Meng M.S., Bishop C. Isolation and characterization of apolipoproteins A-I, A-II and A-IV. Methods Enzymol. 128:1986;223-246.
63. Rall S.C.J., Weisgraber K.H., Mahley R.W. Isolation and characterization of apolipoprotein E. Methods Enzymol. 128:1986;273-287.
64. Peitsch M.C., Kress A., Lerch P.G., Morgenthaler J.J., Isliker, Heiniger HJ. A purification method for apolipoprotein A-I and A-II. Anal Biochem 1989;178: 301-305.
65. Lerch P.G., Fortsch V., Hodler G., Bolli R. Production and characterization of a reconstituted high density lipoprotein for therapeutic applications. Vox. Sanguinis. 71:1996;155-164.
66. Bruhn H., Stoffel W. An approach to the functional analysis of lecithin-cholesterol acyltransferase. Activation by recombinant normal and mutagenized apolipoprotein AI. Biol. Chem. Hoppe-Seyler. 372:1991;225-234.
67. Minnich A., Collet X., Roghani A., Cladaras C., Hamilton R.L., Fielding C.J., Zannis V.I. Site-directed mutagenesis and structure-function analysis of the human apolipoprotein A-I. Relation between lecithin-cholesterol acyltransferase activation and lipid binding. J. Biol. Chem. 267:1992;16553-16560.
68. Sorci Thomas M., Kearns M.W., Lee J.P. Apolipoprotein A-I domains involved in lecithin-cholesterol acyltransferase activation. Structure:function relationships. J. Biol. Chem. 268:1993;21403-21409.
69. Holvoet P., Zhao Z., Vanloo B., Vos R., Deridder E., Dhoest A., Taveirne J., Brouwers E., Demarsin E., Engelborghs Y., Rosseneu M., Collen D., Brasseur R. Phospholipid binding and lecithin-cholesterol acyltransferase activation properties of apolipoprotein A-I mutants. Biochemistry. 34:1995;13334-13342.
70. Davidson W.S., Hazlett T., Mantulin W.W., Jonas A. The role of apolipoprotein AI domains in lipid binding. Proc. Natl. Acad. Sci. USA. 93:1996;13605-13610.
71. Sorci-Thomas M.G., Parks J.S., Kearns M.W., Pate G.N., Zhang C., Thomas M.J. High level secretion of wild-type and mutant forms of human proapoA-I using baculovirus-mediated Sf-9 cell expression. J. Lipid Res. 37:1996;673-683.
72. Holvoet P., Zhao Z., Deridder E., Dhoest A., Collen D. Effects of deletion of the carboxyl-terminal domain of apo A-I or of its substitution with helices of apo A-II on in vitro and in vivo lipoprotein association. J. Biol. Chem. 271:1996;19395-19401.
73. Sorci-Thomas M.G., Curtiss L., Parks J.S., Thomas M.J., Kearns M.W. Alteration in apolipoprotein A-I 22-mer repeat order results in a decrease in lecithin:cholesterol acyltransferase reactivity. J. Biol. Chem. 272:1997;7278-7284.
74. Frank P.G., Bergeron J., Emmanuel F., Lavigne J.P., Sparks D.L., Denefle P., Rassart E., Marcel Y.L. Deletion of central alpha-helices in human apolipoprotein A-I: effect on phospholipid association. Biochemistry. 36:1997;1798-1806.
75. Laccotripe M., Makrides S.C., Jonas A., Zannis V.I. The carboxyl-terminal hydrophobic residues of apolipoprotein A-I affect its rate of phospholipid binding and its association with high density lipoprotein. J. Biol. Chem. 272:1997;17511-17522.
76. Mallory J.B., Kushner P.J., Protter A.A., Cofer C.L., Appleby V.L., Lau K., Schilling J.W., Vigne J.L. Expression and characterization of human apolipoprotein A-I in Chinese hamster ovary cells. J. Biol. Chem. 262:1987;4241-4247.
77. Lamon-Fava S., Ordovas J.M., Mandel G., Forte T.M., Goodman R.H., Schaefer E.J. Secretion of apolipoprotein A-I in lipoprotein particles following transfection of the human apolipoprotein A-I gene into 3T3 cells. J. Biol. Chem. 262:1987;8944-8947.
78. Roghani A., Zannis V.I. Alterations of the glutamine residues of human apolipoprotein AI propeptide by in vitro mutagenesis. Characterization of the normal and mutant protein forms. Biochemistry. 27:1988;7428-7435.
79. Ruiz-Opazo N., Zannis V.I. Expression of the human apolipoprotein A-I gene in rat myogenic L6E9 cells. DNA methylation and regulation of gene activity. J. Biol. Chem. 263:1988;1739-1744.
80. Fennewald S.M., Hamilton R.L.J., Gordon J.I. Expression of human preproapo AI and pre(delta pro)apoAI in a murine pituitary cell line (AtT-20). A comparison of their intracellular compartmentalization and lipid affiliation. J. Biol. Chem. 263:1988;15568-15577.
81. McLeod R.S., Robbins C., Burns A., Yao Z., Pritchard P.H. Deletion of the propeptide of apolipoprotein A-I impairs exit of nascent apolipoprotein A-I from the endoplasmic reticulum. Biochem. J. 302:1994;641-648.
82. Forte T.M., McCall M.R., Amacher S., Nordhausen R.W., Vigne J.L., Mallory J.B. Physical and chemical characteristics of apolipoprotein A-I-lipid complexes produced by Chinese hamster ovary cells transfected with the human apolipoprotein A-I gene. Biochim. Biophys. Acta. 1047:1990;11-18.
83. Lorenzetti R., Sidoli A., Palomba R., Monaco L., Martineau D., Lappi D., Soria M. Expression of the human apolipoprotein A-I gene fused to the E. Coli gene for b-galactosidase. FEBS Lett. 194:1986;343-346.
84. Monaco L., Bond H.M., Howell K.E., Cortese R. A recombinant apo A-I-protein A hybrid reproduces the binding parameters of HDL to its receptor. EMBO J. 6:1987;3253-3260.
85. Brissette L., Cahuzac Bec N., Desforges M., Bec J.L., Marcel Y.L., Rassart E. Expression of recombinant human apolipoprotein A-I in Chinese hamster ovary cells and Escherichia coli. Protein. Expr. Purif. 2:1991;296-303.
86. Moguilevsky N., Roobol C., Loriau R., Guillaume J.P., Jacobs, Cravador A., Herzog A., Brouwers L., Scarso A., Gilles P. Production of human recombinant proapolipoprotein A-I in Escherichia coli: purification and biochemical characterization. Dna 1989;8:429-436.
87. Moguilevsky N., Varsalona F., Guillaume J.P., Gilles P., Bollen A., Roobol K. Production of authentic human proapolipoprotein A-I in Escherichia coli: strategies for the removal of the amino-terminal methionine. J. Biotechnol. 27:1993;159-172.
88. Pyle L.E., Sawyer W.H., Fujiwara Y., Mitchell A., Fidge N.H. Structural and functional properties of full-length and truncated human proapolipoprotein AI expressed in Escherichia coli. Biochemistry. 35:1996;12046-12052.
89. McGuire K.A., Davidson W.S., Jonas A. High yield overexpression and characterization of human recombinant proapolipoprotein A-I. J. Lipid Res. 37:1996;1519-1528.
90. Saku K., Liu R., Ohkubo K., Bai H., Hirata K., Yamamoto K., Morimoto Y., Yamada K., Arakawa K. In vivo conversion of recombinant human proapolipoprotein AI (rh-Met-proapo AI) to apolipoprotein AI in rabbits. Biochim. Biophys. Acta. 1167:1993;257-263.
91. Isacchi A., Sarmientos P., Lorenzetti R., Soria M. Mature apolipoprotein AI and its precursor proApo AI: influence of the sequence at the 5′ end of the gene on the efficiency of expression in Escherichia coli. Gene. 81:1989;129-137.
92. Bergeron J., Frank P.G., Emmanuel F., Latta M., Zhao Y., Sparks D.L., Rassart E., Denefle P., Marcel Y.L. Characterization of human apolipoprotein A-I expressed in Escherichia coli. Biochim. Biophys. Acta. 1344:1997;139-152.
93. Moguilevsky N., Guillaume J.P., Varsalona F., Bulinckx M., Bollen A. Correct in vivo processing of a chimeric ubiquitin-proapolipoprotein A-I fusion protein in baculovirus-infected insect cells. J. Biotechnol. 32:1994;39-43.
94. Pyle L.E., Barton P., Fujiwara Y., Mitchell A., Fidge N. Secretion of biologically active human proapolipoprotein A-I in a baculovirus-insect cell system: protection from degradation by protease inhibitors. J. Lipid Res. 36:1995;2355-2361.
95. Pyle L.E., Fidge N.H., Barton P.A., Luong A., Sviridov D. Production of mature human apolipoprotein A-I in a baculovirus-insect cell system: propeptide is not essential for intracellular processing but may assist rapid secretion. Anal. Biochem. 253:1997;253-258.
96. Vogel T., Weisgraber K.H., Zeevi M.I. Human apolipoprotein E expression in Escherichia coli: structural and functional identity of the bacterially produced protein with plasma apolipoprotein E. Proc Natl Acad Sci USA 1985;82:8696-8700.
97. Lalazar A., Weisgraber K.H., Rall S.C.J., Giladi H., Innerarity T.L., Levanon A.Z., Boyles J.K., Amit B., Gorecki M., Mahley R.W., Vogel T. Site-specific mutagenesis of human apolipoprotein E. Receptor binding activity of variants with single amino acid substitutions. J. Biol. Chem. 263:1988;3542-3545.
98. Shibui T., Uchida-Kazimoto M., Okazaki H. High-level secretion of human apolipoprotein E produced in Escherichia coli: use of a secretion plasmid containing tandemly polymerized ompF-hybrid gene. J. Biotechnol. 17:1991;109-120.
99. Sturley S.L., Culbertson M.R., Attie A.D. Secretion and lipid association of human apolipoprotein E in Saccharomyces cerevisiae requires a host mutation in sterol esterification and uptake. J. Biol. Chem. 266:1991;16273-16276.
100. Gretch D.G., Sturley S.L., Friesen P.D., Beckage N.E., Attie A.D. Baculovirus-mediated expression of human apolipoprotein E in Manduca sexta larvae generates particles that bind to the low density lipoprotein receptor. Proc. Natl. Acad. Sci. USA. 88:1991;8530-8533.
101. Mahley R.W., Weisgraber K.H., Hussain M.M., Greenman B., Fisher M.L., Vogel T., Gorecki M. Intravenous infusion of apolipoprotein E accelerates clearance of plasma lipoproteins in rabbits. J. Clin. Invest. 83:1989;2125-2130.
102. Liang H.Q., Rye K.A., Barter P.J. Cycling of apolipoprotein A-I between lipid-associated and lipid-free pools. Biochim. Biophys. Acta. 1257:1995;31-37.
103. Oram J.F., Yokoyama S. Apolipoprotein-mediated removal of cellular cholesterol and phospholipids. J. Lipid Res. 37:1996;2473-2491.
104. Nanjee M.N., Crouse J.R., King J.M., Hovorka R., Rees S.E., Carson E.R., Morgenthaler J.J., Miller N.E., Lerch P. Effects of intravenous infusion of lipid-free apo A-I in humans. Arterioscler. Thromb. Vasc. Biol. 16:1996;1203-1214.
105. Yamada N., Shimano H., Mokuno H., Ishibashi S., Gotohda T., Kawakami M., Watanabe Y., Akanuma Y., Murase T., Takaku F. Increased clearance of plasma cholesterol after injection of apolipoprotein E into Watanabe heritable hyperlipidemic rabbits. Proc. Natl. Acad. Sci. USA. 86:1989;665-669.
106. Forte T.M., Norum K.R., Glomset J.A., Nichols A.V. Plasma lipoproteins in familial lecithin:cholesterol acyltransferase deficiency. Structure of low and high density lipoproteins as revealed by electron microscopy. J. Clin. Invest. 50:1971;1141-1148.
107. Jonas A. Reconstitution of high-density lipoproteins. Methods Enzymol. 128:1986;553-582.
108. Pownall H.J., Massey J.B., Kusserow S.K., Gotto A.M.J. Kinetics of lipid-protein interactions: interaction of apolipoprotein A-I from human plasma high density lipoproteins with phosphatidylcholines. Biochemistry. 17:1978;1183-1188.
109. Wetterau J.R., Jonas A. Effect of dipalmitoylphosphatidylcholine vesicle curvature on the reaction with human apolipoprotein A-I. J. Biol. Chem. 257:1982;10961-10966.
110. Tajima S., Yokoyama S., Yamamoto A. Effect of lipid particle size on association of apolipoproteins with lipid. J. Biol. Chem. 258:1983;10073-10082.
111. Jonas A., Mason W.R. Interactions of dipalmitoyl- and dimyristoylphosphatidylcholines and their mixtures with apolipoprotein A-I. Biochemistry. 20:1981;3801-3805.
112. Matz C.E., Jonas A. Micellar complexes of human apolipoprotein A-I with phosphatidylcholines and cholesterol prepared from cholate-lipid dispersions. J. Biol. Chem. 257:1982;4535-4540.
113. Bonomo E.A., Swanson M.E. A rapid method for the synthesis of protein-lipid complexes using adsorption chromatography. J. Lipid Res. 29:1988;380-384.
114. Wetterau J.R., Jonas A. Factors affecting the size of complexes of dipalmitoylphosphatidylcholine with human apolipoprotein A-I. J. Biol. Chem. 258:1983;2637-2643.
115. Jonas A., Kezdy K.E., Wald J.H. Defined apolipoprotein A-I conformations in reconstituted high density lipoprotein discs. J. Biol. Chem. 264:1989;4818-4824.
116. Calabresi L., Meng Q.H., Castro G.R., Marcel Y.L. Apolipoprotein A-I conformation in discoidal particles: evidence for alternate structures. Biochemistry. 32:1993;6477-6484.
117. Franceschini G., Werba J.P., Calabresi L. Drug control of reverse cholesterol transport. Pharmacol. Ther. 61:1994;289-324.
118. Hubsch A.P., Casas A.T., Doran J.E. Protective effects of reconstituted high-density lipoprotein in rabbit gram-negative bacteremia models. J. Lab. Clin. Med. 126:1995;548-558.
119. Casas A.T., Hubsch A.P., Rogers B.C., Doran J.E. Reconstituted high-density lipoprotein reduces LPS-stimulated TNF alpha. J. Surg. Res. 59:1995;544-552.
120. Casas A.T., Hubsch A.P., Doran J.E. Effects of reconstituted high-density lipoprotein in persistent gram-negative bacteremia. Am. Surg. 62:1996;350-355.
121. Trachtenberg J.D., Cochrane H., Sun S., Sauther M., Lassere M., Choi E., Li A.P., Callow A.D. Apolipoprotein A-I inhibits atherosclerotic lesions progression. Circulation. 88:1993;1-552.
122. Mezdour H., Yamamura T., Nomura S., Yamamoto A. Exogenous supply of artificial lipoproteins does not decrease susceptibility to atherosclerosis in cholesterol-fed rabbits. Atherosclerosis. 113:1995;237-246.
123. Miyazaki A., Sakuma S., Morikawa W., Takiue T., Miake F., Terano T., Sakai M., Hakamata H., Sakamoto Y., Naito M., Ruan Y., Takahashi K., Ohta T., Horiuchi S. Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits. Arterioscler. Thromb. Vasc. Biol. 15:1995;1882-1888.
124. Yamada N., Inoue I., Kawamura M., Harada K., Watanabe Y., Shimano H., Gotoda T., Shimada M., Kohzaki K., Tsukada T., Shiomi M., Yazaki Y. Apolipoprotein E prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits. J. Clin. Invest. 89:1992;706-711.
125. Carlson L.A. Effect of a single infusion of recombinant human proapolipoprotein A-I liposomes (synthetic HDL) on plasma lipoproteins in patients with low high density lipoprotein cholesterol. Nutr. Metab. Cardiovasc. Dis. 5:1995;85-91.
126. Lacko A.G., Miller N.E. International symposium on the role of HDL in disease prevention: report on a meeting. J. Lipid Res. 38:1997;1267-1273.
127. Pajkrt D., Doran J.E., Koster F., Lerch P.G., Arnet B., van der Poll T., Cate J.W., van Deventer S.J. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J. Exp. Med. 184:1996;1601-1608.
128. Pajkrt D., Lerch P.G., van der Poll T., Levi M., Illi M., Doran J.E., Arnet B., Van den Ende A., ten Cate J.W., van Deventer S.J. Differential effects of reconstituted high-density lipoprotein on coagulation, fibrinolysis and platelet activation during human endotoxemia. Thromb. Haemost. 77:1997;303-307.
129. Ross R. The pathogenesis of athersclerosis: a perspective for the 1990s, Nature 362 (1993) 801-809.
130. The IFNB Multiple Sclerosis Study Group Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
131. Raper S.E., Grossman M., Rader D.J., Thoene J.G., Clark B.J., Kolansky D.M., Muller D.W., Wilson J.M. Safety and feasibility of liver-directed ex vivo gene therapy for homozygous familial hypercholesterolemia. Ann. Surg. 223:1996;116-126.
132. Kopfler W.P., Willard M., Betz T., Willard J.E., Gerard R.D., Meidell R.S. Adenovirus-mediated transfer of a gene encoding human apolipoprotein A-I into normal mice increases circulating high-density lipoprotein cholesterol. Circulation. 90:1994;1319-1327.
133. Stevenson S.C., Marshall Neff J., Teng B., Lee C.B., Roy S., McClelland A. Phenotypic correction of hypercholesterolemia in apo E-deficient mice by adenovirus-mediated in vivo gene transfer. Arterioscler. Thromb. Vasc. Biol. 15:1995;479-484.
134. Schumacher B., Pecher P., von Specht B.U., Stegmann T. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation. 97:1998;645-650.
135. Henry T.D., Rocha-Sing S., Isner J.M. Results of intracoronary recombinant human vascular endothelial growth factor (rhVEGF) administration trial. J. Am. Coll. Cardiol. 31:1998;65.
136. Henry T.D. Can we really grow new blood vessels? Lancet. 351:1998;1826-1827.
137. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344: 1383-1389.
138. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., Macfarlane P.W., McKillop J.H., Packard C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333:1995;1301-1307.
139. MacIsaac A.I., Thomas J.D., Topol E.J. Toward the quiescent coronary plaque. J. Am. Coll. Cardiol. 22:1993;1228-1241.
140. Takagi T., Yoshida K., Akasaka T., Hozumi T., Morioka S., Yoshikawa J. Intravascular ultrasound analysis of reduction in progression of coronary narrowing by treatment with pravastatin. Am. J. Cardiol. 79:1997;1673-1676.
141. Wenke K., Meiser B., Thiery J., Nagel D., von Scheidt W., Steinbeck G., Seidel D., Reichart B. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation. 96:1997;1398-1402.
142. Bauters C., van Belle E., Meurice T., Letourneau T., Lablanche J.-M., Bertrand M.E. Prevention of restenosis. Future directions. Trends Cardiovasc. Med. 7:1997;90-94.
143. Pignoli P., Tremoli E., Poli A., Oreste P., Paoletti R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation. 74:1986;1399-1406.
144. Mercuri M., Bond M.G., Sirtori C.R., Veglia F., Crepaldi G., Feruglio F.S., Descovich G., Ricci G., Rubba P., Mancini M., Gallus G., Bianchi G., D'Alo G., Ventura A. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. Am. J. Med. 101:1996;627-634.
145. Faletra F., Cipriani M., De Chiara F., Quattrocchi G., Danzi G.B., Gronda E., Frigerio M., Mangiavacchi M., Pezzano A. Imaging the left anterior descending coronary artery by high-frequency transthoracic echocardiography in heart transplant patients. Am. J. Cardiol. 75:1995;855-858.
146. Achenbach S., Kessler W., Moshage W.E., Ropers D., Zink D., Kroeker R., Nitz W., Laub G., Bachmann K. Visualization of the coronary arteries in three-dimensional reconstructions using respiratory gated magnetic resonance imaging. Coron. Artery Dis. 8:1997;441-448.
147. Franceschini G. Apolipoprotein function in health and disease: insights from natural mutations. Eur. J. Clin. Invest. 26:1996;733-746.
148. Kunitake S.T., Jarvis M.R., Hamilton R.L., Kane J.P. Binding of transition metals by apolipoprotein A-I-containing plasma lipoproteins: inhibition of oxidation of low density lipoproteins. Proc Natl Acad Sci USA. 89:1992;6993-6997.
149. Suc I., Escargueil-Blanc I., Troly M., Salvayre R., Negre-Salvayre A. HDL and Apo A prevent cell death of endothelial cells induced by oxidized LDL. Arterioscler. Thromb. Vasc. Biol. 17:1997;2158-2166.
150. Miyazaki A., Sakai M., Suginohara Y., Hakamata H., Sakamoto Y., Morikawa W., Horiuchi S. Acetylated low density lipoprotein reduces its ligand activity for the scavenger receptor after interaction with reconstituted high density lipoprotein. J. Biol. Chem. 269:1994;5264-5269.
151. Moudry R., Spycher M.O., Doran J.E. Reconstituted high density lipoprotein modulates adherence of polymorphonuclear leukocytes to human endothelial cells. Shock. 7:1997;175-181.
152. Blackburn W.D.J., Dohlman J.G., Venkatachalapathi Y.V., Pillion D.J., Koopman W.J., Segrest J.P., Anantharamaiah G.M. Apolipoprotein A-I decreases neutrophil degranulation and superoxide production. J. Lipid Res. 32:1991;1911-1918.
153. Massamiri T., Tobias P.S., Curtiss L.K. Structural determinants for the interaction of lipopolysaccharide binding protein with purified high density lipoproteins: role of apolipoprotein A-I. J. Lipid Res. 38:1997;516-525.
154. Flegel W.A., Baumstark M.W., Weinstock C., Berg A., Northoff. Prevention of endotoxin-induced monokine release by human low- and high-density lipoproteins and by apolipoprotein A-I. Infect Immun 1993;61:5140-5146.
155. Yui Y., Aoyama T., Morishita H., Takahashi M., Takatsu Y., Kawai C. Serum prostacyclin stabilizing factor is identical to apolipoprotein A-I (apo A-I). A novel function of apo A-I. J. Clin. Invest. 82:1988;803-807.
156. Vinals M., Martinez-Gonzalez J., Badimon J.J., Badimon L. HDL-induced prostacyclin release in smooth muscle cells is dependent on cyclooxygenase-2 (Cox-2). Arterioscler. Thromb. Vasc. Biol. 17:1997;3481-3488.
157. Saku K., Ahmad M., Glass-Greenwalt P., Kashyap M.L. Activation of fibrinolysis by apolipoproteins of high density lipoproteins in man. Thromb. Res. 39:1985;1-8.
158. Epand R.M., Stafford A., Leon B., Lock P.E., Tytler E.M., Segrest J.P., Anantharamaiah G.M. HDL and apolipoprotein A-I protect erythrocytes against the generation of procoagulant activity. Arterioscler. Thromb. 14:1994;1775-1783.
159. Hamilton K.K., Zhao J., Sims P.J. Interaction between apolipoproteins A-I and A-II and the membrane attack complex of complement. Affinity of the apoproteins for polymeric C9. J. Biol. Chem. 268:1993;3632-3638.